Clinical trial · Observational
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
NCT05837884CI-TRIAL-00121554recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions. Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.
- description
- Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein
- interventionNames
- Diagnostic Test: blood sampling
- label
- Control group
- description
- The individuals without a relative of a patient with a plasma cell dyscrasia or another blood cancer. This group will undergo the same procedures as the first-degree participants and these data will be used for comparison between the populations.
- interventionNames
- Diagnostic Test: blood sampling
Primary outcomes (1)
- measure
- Prevalence and Incidence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Must meet criteria of the high-risk population as described with one of the below criteria * ≥ 30 years AND * first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer. OR * Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer ' * Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care Exclusion Criteria: * • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy. * Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia * Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.
References
Publications (0)
Data not yet available
No reference posted for this study.